Evidence map›Paper›PMID 39263145›Full record

ReviewHeliyon2024

Current insights and future directions of LncRNA Morrbid in disease pathogenesis.

Haiqiong Yang, Jiali Gao, Zaiyong Zheng, Yang Yu, Chunxiang Zhang

Abstract readReview
In one paragraph

Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Haiqiong YangDepartment of Cardiology, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Jiali GaoSchool of Pharmacy, Southwest Medical University, Luzhou, China.
Zaiyong ZhengDepartment of Cardiology, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Yang YuDepartment of Cardiology, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Chunxiang ZhangDepartment of Cardiology, The Affiliated Hospital, Southwest Medical University, Luzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-coding RNAs have emerged as important regulators of gene expression and contributors to many diseases. LncRNA Morrbid, a long non-coding RNA, has been widely studied in recent years. Current literature reports that lncRNA Morrbid is involved in various diseases such as tumors, cardiovascular diseases, inflammatory diseases and metabolic disorder. However, controversial conclusions exist in current studies. As a potential therapeutic target, it is necessary to comprehensively review the current evidence. In this work, we carefully review the literature on Morrbid and discuss each of the hot topics related to lncRNA Morrbid.

Indexed as

Cardiovascular diseaseLncRNA MorrbidLong non-coding RNAMIR4435-2HGTumor

Identifiers

PMID39263145
PMCPMC11388785

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.